| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/14/2004 | CN1468253A 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/14/2004 | CN1468252A 6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/14/2004 | CN1468240A Derivatives of variolin b |
| 01/14/2004 | CN1468236A Novel anticholinergic agents that can be used as medicaments and method for the production thereof |
| 01/14/2004 | CN1468232A Heterocyclic sodium/proton exchange inhibitors and method |
| 01/14/2004 | CN1468227A Non-imidazole aryloxyalkylamines |
| 01/14/2004 | CN1468221A Non-imidazole aryloxypiperidines |
| 01/14/2004 | CN1468209A Stable salts of o-acetylsalicyclic with basic amino acids |
| 01/14/2004 | CN1468144A Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 01/14/2004 | CN1468112A The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 01/14/2004 | CN1468111A A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 01/14/2004 | CN1468110A Combinations of statins, estrogenic agents and optionally estrogens |
| 01/14/2004 | CN1468105A Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 01/14/2004 | CN1468104A Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 01/14/2004 | CN1468102A Modified prodrug forms of ap/amp |
| 01/14/2004 | CN1468089A Microparticles for delivery of the heterologous nucleic acids |
| 01/14/2004 | CN1468060A Oil/fat composition |
| 01/14/2004 | CN1468059A Oil/fat composition |
| 01/14/2004 | CN1466994A Compositions and therapeutic use |
| 01/14/2004 | CN1466939A Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/14/2004 | CN1134452C Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/14/2004 | CN1134253C Oral slow-releasing opioid formulations and method for preparing the same |
| 01/13/2004 | US6678577 Systems and methods for rapidly identifying useful chemicals in liquid samples |
| 01/13/2004 | US6677381 Guaifenesin tannate |
| 01/13/2004 | US6677368 4-aryl substituted indolinones |
| 01/13/2004 | US6677358 NIDDM regimen |
| 01/13/2004 | US6677356 Concurrently administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with angiotensin converting enzyme inhibitor,calcium channel blocker, adrenergic blocking agent, vasodilator or diuretic |
| 01/13/2004 | US6677352 Non-insulin dependent, latent autoimmune, gestational diabetes treatment; impaired glucose tolerance; obesity, hypotensive agents |
| 01/13/2004 | US6677351 Useful in treatment of asthma and inflammation |
| 01/13/2004 | US6677342 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/13/2004 | US6677321 Methods and compositions for treatment of inflammatory disease |
| 01/13/2004 | US6677320 Mixture with chelate compound; bone disorders |
| 01/13/2004 | US6677305 Insulin-like growth factor agonist molecules |
| 01/13/2004 | US6677302 Compositions and methods for the treatment of viral disorders |
| 01/13/2004 | US6677298 Protein antagonist; antidiabetic agents, antilipemic agents |
| 01/13/2004 | US6677133 Methods of reducing microbial resistance to drugs |
| 01/13/2004 | US6677126 Antibody for human translational regulator |
| 01/13/2004 | US6676977 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 01/13/2004 | US6676971 Crosslinked macromolecules |
| 01/13/2004 | US6676950 Administration of at least one antagonist specific for the neurokinin receptor family for inhibiting hiv infection in a patient |
| 01/13/2004 | US6676941 For inhibiting angiogenesis and induce tumor regression; cancer therapy |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/13/2004 | US6676930 Administering dose of mixture of lipid crystals comprising surfactant and spreading agnet as aerosol through an external airway of a mammal for enhancing mammalian eustachian tube lumen patency and pressure equalization performance |
| 01/13/2004 | US6676855 Ethyl nitrite; maintaining circulation to abdominal organs |
| 01/08/2004 | WO2004003562A2 Oncolytic viruses as phenotyping agents for neoplasms |
| 01/08/2004 | WO2004003545A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | WO2004003235A2 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | WO2004003185A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 01/08/2004 | WO2004003179A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004003145A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | WO2004003000A2 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| 01/08/2004 | WO2004002999A2 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 01/08/2004 | WO2004002987A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 01/08/2004 | WO2004002962A1 Novel benzimidazol-2-one derivatives and their use |
| 01/08/2004 | WO2004002957A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/08/2004 | WO2004002948A1 Amide compound and medicinal use thereof |
| 01/08/2004 | WO2004002944A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002940A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002537A1 Worming formulation |
| 01/08/2004 | WO2004002535A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002512A1 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 01/08/2004 | WO2004002500A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | WO2004002485A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 01/08/2004 | WO2004002481A1 Aryl carbonyl derivatives as therapeutic agents |
| 01/08/2004 | WO2004002480A1 Novel glucagon antagonists/inverse agonists |
| 01/08/2004 | WO2004002479A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents |
| 01/08/2004 | WO2004002467A1 Peritoneal dialysate containing taurine |
| 01/08/2004 | WO2004002466A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 01/08/2004 | WO2004002463A2 Method of promoting smoking cessation |
| 01/08/2004 | WO2004002462A2 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| 01/08/2004 | WO2004002461A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002423A2 Cartilage enhancing food supplements with sucralose and methods of preparing the same |
| 01/08/2004 | WO2004002422A2 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | WO2004002421A2 Method for the treatment of multiple sclerosis |
| 01/08/2004 | WO2004002420A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002416A2 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | WO2004002402A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/08/2004 | WO2004002399A2 Use of gaba-c receptor antagonists for the treatment of myopia |
| 01/08/2004 | WO2004002367A1 Drug eluting stent |
| 01/08/2004 | WO2004002296A2 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | WO2004002238A1 Nutritional composition for detoxification and cancer prevention |
| 01/08/2004 | WO2004002226A1 Modulators of cdk9 as a therapeutic target in cardiac hypertrophy |
| 01/08/2004 | WO2003092647A3 Transport system in biological systems |
| 01/08/2004 | WO2003091387A3 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003086279A3 Inhibitors of akt activity |
| 01/08/2004 | WO2003085090A3 A human ribonucleotide reductase m2 subunit |
| 01/08/2004 | WO2003080103A8 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 01/08/2004 | WO2003076445A3 Microtubule stabilizing compounds |
| 01/08/2004 | WO2003075850A3 Methods for alzheimer's disease treatment and cognitive enhancement |
| 01/08/2004 | WO2003075844A3 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 01/08/2004 | WO2003067262A3 Methods and compositions involving the hsp90 activator aha1 |
| 01/08/2004 | WO2003054194A3 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 01/08/2004 | WO2003045965A3 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/08/2004 | WO2003027313A3 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| 01/08/2004 | WO2003020257A3 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 01/08/2004 | WO2003007800A3 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |